Sprint Bioscience
1.314
SEK
-2.52 %
Less than 1K followers
SPRINT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-2.52%
-14.12%
-16.94%
-21.51%
+5.97%
+46%
-58.67%
-76.2%
-88.99%
Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.
Read moreMarket cap
91.74M SEK
Turnover
1.92K SEK
Revenue
65.64M
EBIT %
-29.97 %
P/E
-
Dividend yield-%
-
Financial calendar
7.5
2025
General meeting '25
7.5
2025
Interim report Q1'25
27.8
2025
Interim report Q2'25
ShowingAll content types
Sprint Bioscience presents preclinical data from the TREX1 program at AACR IO
Redeye: Sprint Bioscience Q4 - Confident expansion
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools